Hepatitis Monthly

Published by: Kowsar

Vitamin D Receptor Fok I Polymorphism and Risk of Hepatocellular Carcinoma in HBV-Infected Patients

Jiawei Rao 1 , Xukun Wu 1 , Xiaozhuan Zhou 1 , Ronghai Deng 1 , * and Yi Ma 1 , **
Authors Information
1 Organ Transplantation Center, The First Affiliated Hospital , Sun Yat-sen University, Guangzhou, China
Corresponding Authors:
Article information
  • Hepatitis Monthly: January 31, 2019, 19 (1); e85075
  • Published Online: January 12, 2019
  • Article Type: Review Article
  • Received: October 7, 2018
  • Revised: December 20, 2018
  • Accepted: December 23, 2018
  • DOI: 10.5812/hepatmon.85075

To Cite: Rao J , Wu X, Zhou X, Deng R, Ma Y. Vitamin D Receptor Fok I Polymorphism and Risk of Hepatocellular Carcinoma in HBV-Infected Patients, Hepat Mon. 2019 ; 19(1):e85075. doi: 10.5812/hepatmon.85075.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Methods
3. Results
4. Conclusions
  • 1. Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. Lancet Oncol. 2017;18(2):e101-12. doi: 10.1016/S1470-2045(16)30569-1. [PubMed: 28214411].
  • 2. International Agency for Research on Cancer. Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012.
  • 3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35-50. doi: 10.1053/j.gastro.2004.09.014. [PubMed: 15508101].
  • 4. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5-S16. doi: 10.1053/j.gastro.2004.09.011. [PubMed: 15508102].
  • 5. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557-76. doi: 10.1053/j.gastro.2007.04.061. [PubMed: 17570226].
  • 6. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: A global and regional perspective. Oncologist. 2010;15 Suppl 4:5-13. doi: 10.1634/theoncologist.2010-S4-05. [PubMed: 21115576].
  • 7. Tarocchi M, Polvani S, Marroncini G, Galli A. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol. 2014;20(33):11630-40. doi: 10.3748/wjg.v20.i33.11630. [PubMed: 25206269]. [PubMed Central: PMC4155355].
  • 8. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335-52. doi: 10.1016/j.jhep.2007.11.011. [PubMed: 18096267].
  • 9. Kushner T, Serper M, Kaplan DE. Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes. J Hepatol. 2015;63(3):586-92. doi: 10.1016/j.jhep.2015.04.025. [PubMed: 25962883]. [PubMed Central: PMC4574953].
  • 10. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, et al. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155(4):323-31. doi: 10.1093/aje/155.4.323. [PubMed: 11836196].
  • 11. Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, Wang N, et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology. 2002;36(5):1214-20. doi: 10.1053/jhep.2002.36366. [PubMed: 12395332].
  • 12. Bouchard MJ, Navas-Martin S. Hepatitis B and C virus hepatocarcinogenesis: Lessons learned and future challenges. Cancer Lett. 2011;305(2):123-43. doi: 10.1016/j.canlet.2010.11.014. [PubMed: 21168955]. [PubMed Central: PMC3071446].
  • 13. Gu X, Qi P, Zhou F, Ji Q, Wang H, Dou T, et al. +49G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol. 2010;71(1):83-7. doi: 10.1016/j.humimm.2009.09.353. [PubMed: 19778566].
  • 14. Chou YC, Yu MW, Wu CF, Yang SY, Lin CL, Liu CJ, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut. 2008;57(1):91-7. doi: 10.1136/gut.2006.114066. [PubMed: 17502344].
  • 15. Jiang DK, Sun J, Cao G, Liu Y, Lin D, Gao YZ, et al. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet. 2013;45(1):72-5. doi: 10.1038/ng.2483. [PubMed: 23242368]. [PubMed Central: PMC4105840].
  • 16. Fedirko V, Duarte-Salles T, Bamia C, Trichopoulou A, Aleksandrova K, Trichopoulos D, et al. Prediagnostic circulating vitamin D levels and risk of hepatocellular carcinoma in European populations: A nested case-control study. Hepatology. 2014;60(4):1222-30. doi: 10.1002/hep.27079. [PubMed: 24644045].
  • 17. Ghous Z, Akhter J, Pourgholami MH, Morris DL. Inhibition of hepatocellular cancer by EB1089: In vitro and in vive study. Anticancer Res. 2008;28(6A):3757-61. [PubMed: 19189661].
  • 18. Pourgholami MH, Akhter J, Lu Y, Morris DL. In vitro and in vivo inhibition of liver cancer cells by 1,25-dihydroxyvitamin D3. Cancer Lett. 2000;151(1):97-102. doi: 10.1016/S0304-3835(99)00416-4. [PubMed: 10766428].
  • 19. Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ, et al. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer. 2003;89(2):252-7. doi: 10.1038/sj.bjc.6601104. [PubMed: 12865912]. [PubMed Central: PMC2394267].
  • 20. Norman AW. Minireview: Vitamin D receptor: New assignments for an already busy receptor. Endocrinology. 2006;147(12):5542-8. doi: 10.1210/en.2006-0946. [PubMed: 16946007].
  • 21. Chiang KC, Chen TC. Vitamin D for the prevention and treatment of pancreatic cancer. World J Gastroenterol. 2009;15(27):3349-54. doi: 10.3748/wjg.15.3349. [PubMed: 19610135]. [PubMed Central: PMC2712895].
  • 22. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab. 2010;95(2):471-8. doi: 10.1210/jc.2009-1773. [PubMed: 20133466]. [PubMed Central: PMC2840860].
  • 23. Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol. 2001;177(1-2):145-59. [PubMed: 11377830].
  • 24. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338(2):143-56. doi: 10.1016/j.gene.2004.05.014. [PubMed: 15315818].
  • 25. Mohammed MA, Shabana H, Sheta T, Omar NM, Mohammed SA. Vitamin D receptor gene polymorphisms as a predictive risk factor for hepatocellular carcinoma development and severity in chronic hepatitis B. Int J Cancer Res. 2016;13(1):26-35. doi: 10.3923/ijcr.2017.26.35.
  • 26. Peng Q, Yang S, Lao X, Li R, Chen Z, Wang J, et al. Association of single nucleotide polymorphisms in VDR and DBP genes with HBV-related hepatocellular carcinoma risk in a Chinese population. PLoS One. 2014;9(12). e116026. doi: 10.1371/journal.pone.0116026. [PubMed: 25541958]. [PubMed Central: PMC4277456].
  • 27. Yao X, Zeng H, Zhang G, Zhou W, Yan Q, Dai L, et al. The associated ion between the VDR gene polymorphisms and susceptibility to hepatocellular carcinoma and the clinicopathological features in subjects infected with HBV. Biomed Res Int. 2013;2013:953974. doi: 10.1155/2013/953974. [PubMed: 23586065]. [PubMed Central: PMC3618929].
  • 28. Falleti E, Bitetto D, Fabris C, Cussigh A, Fontanini E, Fornasiere E, et al. Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J Gastroenterol. 2010;16(24):3016-24. doi: 10.3748/wjg.v16.i24.3016. [PubMed: 20572305]. [PubMed Central: PMC2890942].
  • 29. Huang YW, Liao YT, Chen W, Chen CL, Hu JT, Liu CJ, et al. Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. Genes Immun. 2010;11(1):87-93. doi: 10.1038/gene.2009.65. [PubMed: 19693091].
  • 30. Sarkissyan M, Wu Y, Chen Z, Mishra DK, Sarkissyan S, Giannikopoulos I, et al. Vitamin D receptor Fok I gene polymorphisms may be associated with colorectal cancer among African American and Hispanic participants. Cancer. 2014;120(9):1387-93. doi: 10.1002/cncr.28565. [PubMed: 24510435]. [PubMed Central: PMC3999299].
  • 31. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology. 2002;35(1):126-31. doi: 10.1053/jhep.2002.30084. [PubMed: 11786968].
  • 32. Shafia S, Qasim I, Aziz SA, Bhat IA, Nisar S, Shah ZA. Role of vitamin D receptor (VDR) polymorphisms in susceptibility to multiple myeloma in ethnic Kashmiri population. Blood Cells Mol Dis. 2013;51(1):56-60. doi: 10.1016/j.bcmd.2013.02.001. [PubMed: 23453529].
  • 33. Hager G, Formanek M, Gedlicka C, Thurnher D, Knerer B, Kornfehl J. 1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol. 2001;121(1):103-9. doi: 10.1080/000164801300006353. [PubMed: 11270487].
  • 34. Saramaki A, Banwell CM, Campbell MJ, Carlberg C. Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res. 2006;34(2):543-54. doi: 10.1093/nar/gkj460. [PubMed: 16434701]. [PubMed Central: PMC1351372].
  • 35. Cheng HT, Chen JY, Huang YC, Chang HC, Hung WC. Functional role of VDR in the activation of p27Kip1 by the VDR/Sp1 complex. J Cell Biochem. 2006;98(6):1450-6. doi: 10.1002/jcb.20780. [PubMed: 16518840].
  • 36. He Q, Huang Y, Zhang L, Yan Y, Liu J, Song X, et al. Association between vitamin D receptor polymorphisms and hepatitis B virus infection susceptibility: A meta-analysis study. Gene. 2018;645:105-12. doi: 10.1016/j.gene.2017.12.027. [PubMed: 29248582].
  • 37. Li J, Shi J, Ren W, Wu W, Chen Z. Regulatory role of CD4(+)CD25 (+)Foxp3 (+) regulatory T cells on IL-17-secreting T cells in chronic hepatitis B patients. Dig Dis Sci. 2014;59(7):1475-83. doi: 10.1007/s10620-013-3022-1. [PubMed: 24442238].
  • 38. Staeva-Vieira TP, Freedman LP. 1,25-dihydroxyvitamin D3 inhibits IFN-gamma and IL-4 levels during in vitro polarization of primary murine CD4+ T cells. J Immunol. 2002;168(3):1181-9. doi: 10.4049/jimmunol.168.3.1181. [PubMed: 11801653].
  • 39. Sochorova K, Budinsky V, Rozkova D, Tobiasova Z, Dusilova-Sulkova S, Spisek R, et al. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol. 2009;133(1):69-77. doi: 10.1016/j.clim.2009.06.011. [PubMed: 19660988].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments